Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong Sells 14,836 Shares

Neuronetics, Inc. (NASDAQ:STIMGet Free Report) CFO Stephen Furlong sold 14,836 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $3.28, for a total transaction of $48,662.08. Following the completion of the transaction, the chief financial officer now owns 482,572 shares in the company, valued at $1,582,836.16. This trade represents a 2.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Neuronetics Price Performance

Shares of NASDAQ:STIM opened at $3.90 on Friday. The firm’s 50 day moving average price is $2.14 and its 200-day moving average price is $1.40. Neuronetics, Inc. has a twelve month low of $0.52 and a twelve month high of $5.07. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90. The stock has a market capitalization of $118.37 million, a PE ratio of -3.17 and a beta of 2.17.

Hedge Funds Weigh In On Neuronetics

Several institutional investors have recently made changes to their positions in STIM. Tradewinds LLC. bought a new position in shares of Neuronetics in the 4th quarter worth approximately $32,000. XTX Topco Ltd bought a new stake in Neuronetics during the 4th quarter worth approximately $49,000. Landscape Capital Management L.L.C. bought a new stake in Neuronetics during the 3rd quarter worth approximately $53,000. GSA Capital Partners LLP raised its stake in Neuronetics by 64.5% during the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after acquiring an additional 30,837 shares during the period. Finally, David J Yvars Group raised its stake in Neuronetics by 47.1% during the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock worth $75,000 after acquiring an additional 14,825 shares during the period. Institutional investors own 53.59% of the company’s stock.

Neuronetics Company Profile

(Get Free Report)

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Featured Stories

Insider Buying and Selling by Quarter for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.